Honokiol, a phytochemical from Magnolia spp., inhibits breast cancer cell migration by targeting nitric oxide and cyclooxygenase-2

International Journal of Oncology

Volumn 38, Issue 3, 2011, Pages 769-776

  Singh, Tripti ^b   Katiyar, Santosh K ^a,b  

^a BIRMINGHAM VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Breast cancer cells; Cancer cell migration; Cyclooxygenase 2; Guanylate cyclase; Honokiol; Nitric oxide; Prostaglandin E2

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 8 BROMO CYCLIC GMP; CYCLIC GMP; CYCLOOXYGENASE 2; HONOKIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROSTAGLANDIN E2;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIPHENYL COMPOUNDS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CYCLOOXYGENASE 2; DRUG EVALUATION, PRECLINICAL; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LIGNANS; MAGNOLIA; MICE; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NITRIC OXIDE; PHYTOTHERAPY;

EID: 79952012897     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.899     Document Type: Article

References (42)

1. American Cancer Society: Cancer facts and figures. Atlanta, GA. American Cancer Society, 2009.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
3. Ali SM, Harvey HA and Lipton A: Metastatic breast cancer: overview of treatment. Clin Orthop Relat Res (Suppl) 415: 132-137, 2003.
4. Lala PK and Orucevic A: Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev 17: 91-106, 1998. (Pubitemid 28194648)
5. Thomsen LL and Miles DW: Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev 17: 107-118, 1998. (Pubitemid 28194649)
6. Moncada S and Higgs EA: The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002-2012, 1993.
7. Knowles RG and Moncada S: Nitric oxide synthases in mammals. Biochem J 298: 249-258, 1994. (Pubitemid 24072462)
8. Lala PK and Chakraborty C: Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2: 149-156, 2001. (Pubitemid 33585926)
9. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC and Moncada S: Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92: 4392-4396, 1995.
10. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA and Ziche M: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 90: 587-596, 1998. (Pubitemid 28204802)
11. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW and Mitchell JB: The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19: 711-721, 1998. (Pubitemid 28376759)
12. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK and Lee SS: Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 480-481: 243-268, 2001. (Pubitemid 32744832)
13. Rajnakova A, Moochhala S, Goh PM and Ngoi S: Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett 172: 177-185, 2001. (Pubitemid 32889714)
14. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M and Härkönen P: Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 29: 23-28, 2001.
15. Wilson KT, Fu S, Ramanujam KS and Meltzer SJ: Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58: 2929-2934, 1998. (Pubitemid 28335064)
16. Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Ogunfusika MO, Oser SM, Klein S, Shields PG, Billiar TR and Harris CC: Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 58: 334-341, 1998. (Pubitemid 28047076)
17. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG and Needleman P: Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 90: 7240-7244, 1993. (Pubitemid 23222425)
18. Salvemini D, Seibert K, Masferrer JL, Misko TP, Currie MG and Needleman P: Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest 93: 1940-1947, 1994.
19. Amin AR, Attur M, Patel RN, Thakker GD, Marshall PJ, Rediske J, Stuchin SA, Patel IR and Abramson SB: Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest 99: 1231-1237, 1997. (Pubitemid 27142759)
20. Davidge ST, Baker PN, Laughlin MK and Roberts JM: Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. Circ Res 77: 274-283, 1995.
21. Kanner J, Harel S and Granit R: Nitric oxide, an inhibitor of lipid oxidation by lipoxygenase, cyclooxygenase and hemoglobin. Lipids 27: 46-49, 1992.
22. Stadler J, Harbrecht BG, DiSilvio M, Curran RD, Jordan ML, Simmons RL and Billiar TR: Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells. J Leukoc Biol 53: 165-172, 1993. (Pubitemid 23100159)
23. Tsai AL, Wei C and Kulmacz RJ: Interaction between nitric oxide and prostaglandin H synthase. Arch Biochem Biophys 313: 367-372, 1994. (Pubitemid 24292815)
24. Li TSC: Chinese and Related North American Herbs. In: Phytopharmacology and Therapeutic Values. CRC Press, Boca Raton, FL, 2002.
25. Hahm ER, Arlotti JA, Marynowski SW and Singh SV: Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin Cancer Res 14: 1248-1257, 2008.
26. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E, Dubiel W, Soff G and Arbiser JL: Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 278: 35501-35507, 2003. (Pubitemid 37102321)
27. Munroe ME, Arbiser JL and Bishop GA: Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J Immunol 179: 753-763, 2007.
28. Pyo MK, Lee Y and Yun-Choi HS: Anti-platelet effect of the constituents isolated from the barks and fruits of Magnolia obovata. Arch Pharm Res 25: 325-328, 2002.
29. Clark AM, El-Feraly FS and Li WS: Antimicrobial activity of phenolic constituents of Magnolia grandiflora L. J Pharm Sci 70: 951-952, 1981.
30. Park J, Lee J, Jung E, Park Y, Kim K, Park B, Jung K, Park E, Kim J and Park D: In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. Eur J Pharmacol 496: 189-195, 2004. (Pubitemid 39024332)
31. Punathil T and Katiyar SK: Inhibition of non-small cell lung cancer cell migration by grape seed proanthocyanidins is mediated through the inhibition of nitric oxide, guanylate cyclase, and ERK1/2. Mol Carcinog 48: 232-242, 2009.
32. Akhtar S, Meeran SM, Katiyar N and Katiyar SK: Grape seed proanthocyanidins inhibit the growth of human non-small cell lung cancer xenografts by targeting IGFBP-3, tumor cell proliferation and angiogenic factors. Clin Cancer Res 15: 821-831, 2009.
33. Mantena SK, Sharma SD and Katiyar SK: Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase-3 and PARP. Carcinogenesis 27: 2018-2027, 2006. (Pubitemid 44530576)
34. Jadeski LC, Hum KO, Chakraborty C and Lala PK: Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 86: 30-39, 2000. (Pubitemid 30133983)
35. Orucevic A, Bechberger J, Green AM, Shapiro RA, Billiar TR and Lala PK: Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer 81: 889-896, 1999. (Pubitemid 29249973)
36. Dannenberg AJ and Subbaramaiah K: Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436, 2003. (Pubitemid 38050040)
37. Riedl K, Krysan K, Põld M, Dalwadi H, Heuze-Vourc'h N, Dohadwala M, Liu M, Cui X, Figlin R, Mao JT, Strieter R, Sharma S and Dubinett SM: Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat 7: 169-184, 2004.
38. Moncada S, Palmer RM and Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142, 1991.
39. 2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 268: 26286-26295, 1993.
40. Habib A, Bernard C, Lebret M, Creminon C, Esposito B, Tedgui A and Maclouf J: Regulation of the expression of cyclooxygenase-2 by nitric oxide in rat peritoneal macrophages. J Immunol 158: 3845-3851, 1997. (Pubitemid 127488743)
41. Liaudet L, Soriano FG and Szabó C: Biology of nitric oxide signaling. Crit Care Med 28: N37-N52, 2000. (Pubitemid 30262046)
42. D'Acquisto F, Maiuri MC, de Cristofaro F and Carnuccio R: Nitric oxide prevents inducible cyclooxygenase expression by inhibiting nuclear factor-kappa B and nuclear factor-interleukin-6 activation. Naunyn Schmiedebergs Arch Pharmacol 364: 157-165, 2001. (Pubitemid 32706702)